HIV单一感染者的肝脂肪变性进展快于HIV/HCV共感染者,且与肝纤维化相关
加拿大前瞻性队列LIVEHIV纳入726例HIV感染者(22.7%合并HCV),用瞬时弹性成像联合CAP筛查脂肪肝和纤维化。HIV单一感染者肝脂肪变性进展率37.8/100人年,高于HIV/HCV共感染者的21.9/100人年;HCV共感染是肝脂肪变性进展的独立负预测因子(aHR 0.50)。肝脂肪变性可预测HIV单一感染者的肝纤维化进展(aHR 4.18),但在HIV/HCV共感染者中无此关联。
要点
- HIV单一感染者肝脂肪变性进展率37.8/100人年,HIV/HCV共感染者21.9/100人年。
- HCV共感染是肝脂肪变性进展的独立负预测因子(aHR 0.50,95%CI 0.28-0.89)。
- 肝脂肪变性预测HIV单一感染者肝纤维化进展(aHR 4.18,95%CI 1.21-14.5),共感染者中无此关联。
核心结论
- 肝脂肪变性在HIV单一感染者中进展更快,且与肝纤维化进展相关;在HIV/HCV共感染者中未见此关联。
研究设计与样本
- 加拿大前瞻性队列研究LIVEHIV,采用瞬时弹性成像及受控衰减参数(CAP)在未选择的HIV感染成人中筛查肝脂肪变性和肝纤维化。
- 共纳入726例HIV感染者,其中22.7%合并HCV感染;313例接受中位15.4个月(四分位距8.5-23.0)随访。
主要发现
- HIV单一感染者与HIV/HCV共感染者任何级别肝脂肪变性患病率分别为36.1%和38.6%。
- 肝脂肪变性进展率在HIV单一感染为37.8/100人年(95%CI 29.2-49.0),在HIV/HCV共感染为21.9/100人年(95%CI 15.6-30.7)。
- HCV共感染是肝脂肪变性进展的独立负预测因子(aHR 0.50,95%CI 0.28-0.89)。
- 肝脂肪变性预测HIV单一感染者的肝纤维化进展(aHR 4.18,95%CI 1.21-14.5),但在HIV/HCV共感染者中不预测肝纤维化进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatic steatosis (HS) seems common in patients infected with human immunodeficiency virus (HIV). However, the relative effect of HIV, as well as hepatitis C virus (HCV) in those co-infected, and the influence of HS on liver fibrosis progression are unclear. METHODS: The LIVEr disease in HIV (LIVEHIV) is a Canadian prospective cohort study using transient elastography and associated controlled attenuation parameter (CAP) to screen for HS and liver fibrosis, in unselected HIV-infected adults. HS progression was defined as development of any grade HS (CAP ⩾248dB/m), or transition to severe HS (CAP >292dB/m), for those with any grade HS at baseline. Fibrosis progression was defined as development of significant liver fibrosis (liver stiffness measurement [LSM] >7.1kPa), or transition to cirrhosis (LSM >12.5kPa) for those with significant liver fibrosis at baseline. Cox regression analysis was used to assess predictors of HS and fibrosis progression. RESULTS: A prospective cohort study was conducted, which included 726 HIV-infected patients (22.7% HCV co-infected). Prevalence of any grade HS did not differ between HIV mono-infected and HIV/HCV co-infected patients (36.1% vs. 38.6%, respectively). 313 patients were followed for a median of 15.4 (interquartile range 8.5-23.0) months. The rate of HS progression was 37.8 (95% confidence interval [CI] 29.2-49.0) and 21.9 (95% CI 15.6-30.7) per 100 person-years in HIV mono-infection and HIV/HCV co-infection, respectively. HCV co-infection was an independent negative predictor of HS progression (adjusted hazard ratio [aHR] 0.50, 95% CI 0.28-0.89). HS predicted liver fibrosis progression in HIV mono-infection (aHR 4.18, 95% CI 1.21-14.5), but not in HIV/HCV co-infection. CONCLUSION: HS progresses faster and is associated with liver fibrosis progression in HIV mono-infection but not in HIV/HCV co-infection. Lay summary: Fatty liver is the most frequent liver disease in Western countries. People living with HIV seem at high risk of fatty liver due to frequent metabolic disorders and the long-term effects of antiretroviral therapy. However, due to the invasiveness of liver biopsy, the traditional method of diagnosing fatty liver, there are few data regarding its frequency in people living with HIV. In this study, we used a non-invasive diagnostic tool to analyze the epidemiology of fatty liver in 726 HIV+ patients. We found that fatty liver affects over one-third of people living with HIV. When followed over time, we found that HIV+ patients without HCV co-infection develop fatty liver more frequently than those co-infected with HCV.
引用
- Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol. 2017. PMID: 28527666. doi:10.1016/j.jhep.2017.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。